Related Experiment Video

Updated: Feb 27, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.3K

Targeting FGFR in Squamous Cell Carcinoma of the Lung

Neda Hashemi-Sadraei1, Nasser Hanna2

  • 1Department of Medicine, Indiana University School of Medicine, 535 Barnhill Drive, RT 400, Indianapolis, IN, 46202, USA. nhashemi@iu.edu.

Targeted Oncology
|July 8, 2017
PubMed

Insights

Targetable fibroblast growth factor receptor (FGFR) aberrations are present in squamous cell lung cancer, offering a new avenue for molecular targeted therapies. FGFR inhibitors show promise for treating this challenging cancer type.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Squamous cell lung cancer (SqCLC) lacks targeted therapies due to scarce oncogenic aberrations.
  • Fibroblast growth factor (FGF) signaling is crucial for tumor angiogenesis and proliferation.
  • FGF pathway aberrations are identified in SqCLC, presenting FGFR as a potential therapeutic target.

Purpose of the Study:

  • To review fibroblast growth factor receptor (FGFR) aberrations in squamous cell lung cancer.
  • To analyze clinical data of FGFR inhibitors in SqCLC treatment.

Main Methods:

  • Comprehensive genomic studies to identify FGF pathway aberrations.
  • Review of clinical trial data for FGFR inhibitors in SqCLC.

Main Results:

  • FGFR aberrations are identified in SqCLC.
  • Multi-targeted and selective FGFR inhibitors are under clinical investigation.
  • Promising preliminary results observed with FGFR inhibitors in SqCLC.

Conclusions:

  • FGFR represents a druggable target in squamous cell lung cancer.
  • FGFR inhibitors, both selective and multi-targeted, offer a promising therapeutic strategy for SqCLC.
  • Further clinical investigation of FGFR inhibitors is warranted for SqCLC treatment.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51